The purpose of this global study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 (50, 100, and 150 mg twice a day [BID]) in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe endometriosis-related pain.